外泌体miR-361-3p通过靶向ETV7和BATF2上调PAI-1 ERK途径促进乳腺癌细胞生存能力

核心信息

  • 论文英文标题: Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway
  • 期刊: J Transl Med
  • 发表年份: 2024
  • DOI: 10.1186/s12967-024-04914-4
  • PMID/PMCID: 38282047; PMC10823750

研究概览

We examined the correlation between miRNA expression in tumor tissues and plasma exosomes in BC patients by qRT‒PCR. Our data suggest that plasma exosomal miR-361-3p has the potential to serve as a biomarker for predicting malignant progression in BC patients.

核心发现

We found that the expression level of plasma exosomal miR-361-3p gradually increased with malignant progression in BC patients, and the expression of miR-361-3p in plasma exosomes and BC tissues was positively correlated.

Consistently, exosomal miR-361-3p enhanced the migration and proliferation of two BC cell lines, MDA-MB-231 and SK-BR-3.

Furthermore, our data showed that miR-361-3p inhibited two novel target genes, ETV7 and BATF2, to activate the PAI-1/ERK pathway, leading to increased BC cell viability.

Finally, the consistency of the in vivo experimental results supported that elevated plasma exosomal miR-361-3p promote the malignant progression of BC.

研究设计

We performed plasma exosomal miRNA sequencing on 45 individuals, including healthy controls and nonmetastatic and metastatic BC patients.

We examined the correlation between miRNA expression in tumor tissues and plasma exosomes in BC patients by qRT‒PCR.

The effects of exosomal miR-361-3p on BC cells were determined by CellTiter-Glo, migration and wound healing assays.

Echo Biotech 角色

血浆外泌体分离鉴定及miRNA测序分析

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway J Transl Med. 2024. DOI: 10.1186/s12967-024-04914-4. PMID/PMCID: 38282047; PMC10823750.